1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,155 | 0,164 | 13:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 22.04. | VIVA BIOTECH (01873): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 1 | HKEx | ||
| 22.04. | VIVA BIOTECH (01873): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | - | HKEx | ||
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 22.04. | VIVA BIOTECH (01873): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 22.04. | VIVA BIOTECH (01873): PROPOSED RE-ELECTION OF RETIRING DIRECTORS PROPOSED RE-APPOINTMENT OF AUDITOR PROPOSALS FOR GRANTING OF GENERAL MANDATES TO ISSUE ... | - | HKEx | ||
| 22.04. | VIVA BIOTECH (01873): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 07.04. | Fifteen Years Alongside Europe's Drug Discovery Teams: Viva Biotech Strengthens Continuity from Discovery to Development and Manufacturing | 549 | PR Newswire | Delivering Continuity in a Changing LandscapeClients across the region view Viva Biotech not just as a service provider, but as a consistent, reliable partner and collaborator, an extension of their... ► Artikel lesen | |
| 30.03. | Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up | 346 | PR Newswire | CRO Business Sustained Recovery in Growth, AI-Enabled Drug Discovery Technology Maintained Industry-Leading AdvantagesThroughout 2025, revenue from the Company's CRO business rose from RMB810.9 million... ► Artikel lesen | |
| 30.03. | Viva Biotech Holdings Full Year Profit Climbs | 1 | RTTNews | ||
| 30.03. | VIVA BIOTECH (01873): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | - | HKEx | ||
| 18.03. | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 1 | HKEx | ||
| 17.03. | Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA | 509 | PR Newswire | SHANGHAI, March 17, 2026 /PRNewswire/ -- Monday, March 16th at 1:30 PM PT, Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting... ► Artikel lesen | |
| 16.02. | VIVA BIOTECH (01873): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | 1 | HKEx | ||
| 16.02. | VIVA BIOTECH (01873): RESIGNATION OF NON-EXECUTIVE DIRECTOR | 2 | HKEx | ||
| 29.01. | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT APPROVAL OF ENVIRONMENTAL IMPACT REPORT FOR LANGHUA PHARMACEUTICAL | 1 | HKEx | ||
| 05.01. | VIVA BIOTECH (01873): UPDATE ANNOUNCEMENT REGARDING DEEMED DISPOSAL AND DISPOSAL OF EQUITY INTEREST IN VIVA SHANGHAI | - | HKEx | ||
| 29.12.25 | Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities | 377 | PR Newswire | SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader... ► Artikel lesen | |
| 15.12.25 | Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. | 490 | PR Newswire | STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which... ► Artikel lesen | |
| 02.12.25 | VIVA BIOTECH (01873): GRANT OF SHARE OPTIONS | 5 | HKEx | ||
| 29.09.25 | Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry | 385 | PR Newswire | Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,540 | +0,95 % | Valneva senkt Prognose und baut Stellen ab | Beim Impfstoffspezialisten Valneva SE häufen sich im ersten Quartal 2026 die Belastungen: Der Nettoverlust weitete sich auf 32,1 Millionen Euro nach 9,2 Millionen Euro im Vorjahr aus, das bereinigte... ► Artikel lesen | |
| NOVONESIS | 51,24 | +0,47 % | Novonesis Q1 Net Profit Rises, Net Sales Up 7% Organically; Backs FY26 Outlook | BRUSSELS (dpa-AFX) - Novonesis A/S (NVZMF.PK, NSIS_B.CO, NSIS-B.CO, NVZMF, NSIS-B) Tuesday said that its first quarter net profit rose from last year, helped by good performances by the Food... ► Artikel lesen | |
| GENMAB | 226,60 | -0,74 % | Genmab A/S: Capital Increase in Genmab as a Result of Employee Warrant Exercise | Company Announcement COPENHAGEN, Denmark; May 12, 2026 - Genmab A/S (Nasdaq: GMAB) will increase its share capital by 2,346 shares as a consequence of the exercise of employee warrants. The increase... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,610 | -1,10 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| BEONE MEDICINES LTD ADR | 258,00 | +2,38 % | BeOne Medicines Ltd.: BEQALZI (Sonrotoclax) von BeOne Medicines von der US-amerikanischen FDA als erster und einziger BCL2-Inhibitor für R/R-Mantelzelllymphom zugelassen | BEQALZI ist ein grundlegender BCL2-Inhibitor, der für höhere Wirkstärke sowie Selektivität entwickelt wurde und gegenüber anderen Wirkstoffen dieser Klasse das Potenzial hat, Wirksamkeit, Verträglichkeit... ► Artikel lesen | |
| SINO BIOPHARM | 0,599 | +1,94 % | SBP GROUP (01177): NEXT DAY DISCLOSURE RETURN | ||
| MUSTGROW BIOLOGICS | 0,328 | 0,00 % | Übernahme bei Bayer! Schock bei Rheinmetall! Chance bei MustGrow Aktie! | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Die Blockade in der Straße von Hormus ist ein Stresstest für die globale Ernährungssicherheit. Die Lieferketten der Düngemittelindustrie... ► Artikel lesen | |
| VERICEL | 28,050 | 0,00 % | Vericel Corporation: Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance | Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91% Gross Margin of 72% and Adjusted EBITDA Growth of 195% Free Cash Flow of $15.1 Million... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,140 | +1,42 % | Moleculin Biotech, Inc.: Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial | Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial First interim unblinding expected in June 2026 following 45 subject... ► Artikel lesen | |
| ZAI LAB LTD ADR | 17,700 | 0,00 % | ZAI LAB (09688): GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS | ||
| SENSEI BIOTHERAPEUTICS | 21,000 | +2,79 % | Sensei Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| BIOXCEL THERAPEUTICS | 1,005 | +1,93 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| REGENXBIO | 5,066 | +3,01 % | XFRA RB0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILREGENXBIO INC. DL-... ► Artikel lesen | |
| AKEBIA | 0,916 | 0,00 % | Akebia Therapeutics verfehlt Gewinnprognose für Q1 2026 - Aktie bricht ein | ||
| ZEVRA THERAPEUTICS | 9,400 | 0,00 % | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare... ► Artikel lesen |
VIVA BIOTECH HOLDINGS gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,155 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.